Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Leo P, Janowczyk A, Elliott R, Janaki N, Bera K, Shiradkar R, et al. Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. NPJ Precis Oncol. 2021;5(1):35.

Naidoo M, Levine F, Gillot T, Orunmuyi AT, E Olapade-Olaopa O, Ali T, et al. MicroRNA-1205 Regulation of FRYL in Prostate Cancer. Front Cell Dev Biol. 2021;9:647485.

Manohar J, Abedian S, Martini R, Kulm S, Salvatore M, Ho K, et al. Social and Clinical Determinants of COVID-19 Outcomes: Modeling Real-World Data from a Pandemic Epicenter. medRxiv. 2021.

Vertesich K, Sosa BR, Niu Y, Ji G, Suhardi V, Turajane K, et al. Alendronate enhances osseointegration in a murine implant model. J Orthop Res. 2021;39(4):719-726.

DeSimone RA, Costa VA, Kane K, Sepulveda JL, Ellsworth GB, Gulick RM, et al. Blood component utilization in COVID-19 patients in New York City: Transfusions do not follow the curve. Transfusion. 2021;61(3):692-698.

Ketas TJ, Chaturbhuj D, Portillo VM, Francomano E, Golden E, Chandrasekhar S, et al. Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in Saliva. Pathog Immun. 2021;6(1):116-134.

Karafin MS, Becker JL, Berg M, DeSimone RA, Draper NL, Hudgins J, et al. Heterogeneity in Approaches for Switching From Universal to Patient ABO Type-Specific Blood Components During Massive Hemorrhage: An International Survey and Review of the Literature. Arch Pathol Lab Med. 2021.

Iannello A, Vitale N, Coma S, Arruga F, Chadburn A, Di Napoli A, et al. Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models. Blood. 2021;137(24):3378-3389.

Wangsiricharoen S, Larman TC, Wakely PE, Siddiqui MT, Ali SZ. Cytopathology of extra-renal perivascular epithelioid cell tumor (PEComa): a series of 7 cases and review of the literature. J Am Soc Cytopathol. 2021;10(2):175-186.

Shigeta S, Lui GY, Shaw R, Moser R, Gurley KE, Durenberger G, et al. Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma. Mol Cancer Ther. 2021;20(4):691-703.